Fisetin's senolytic activity is dose-dependent with a clear threshold effect. In mouse studies, doses below ~50 mg/kg show anti-inflammatory and neuroprotective effects without significant senescent cell clearance, while doses of 100 mg/kg (equivalent to ~8–20 mg/kg in humans after allometric scaling) consistently reduce SA-β-Gal positive cells by 25–50%.
Key Facts
Senolytic threshold: In the Yousefzadeh (2018) study, the senolytic dose in mice was 100 mg/kg. Using standard allometric scaling (divide by 12 for mouse-to-human conversion), this gives a human equivalent of ~8 mg/kg. The 20 mg/kg human protocol builds in a safety factor.
Sub-threshold effects: At 5–10 mg/kg human equivalent doses, fisetin shows anti-inflammatory (NF-κB inhibition), neuroprotective (ERK/CREB activation), and antioxidant effects — beneficial but not senolytic.
Dose-dependent SA-β-Gal reduction: At 100 mg/kg in mice, SA-β-Gal (senescence-associated beta-galactosidase, the gold standard senescence marker) is reduced by ~50%. At 50 mg/kg, reduction is ~25–30%. Below 25 mg/kg, effects are minimal.
Human plasma levels: At 20 mg/kg oral dose in humans, peak fisetin plasma levels reach ~2–5 μM — within the range shown to inhibit BCL-2 family proteins in cell culture experiments (IC50: 1–10 μM).
Bioavailability impact: With standard bioavailability of 10%, a 1,400 mg dose delivers ~140 mg absorbed — equivalent to perhaps 3–5 mg/kg effective dose. High-bioavailability forms (phytosome, liposomal) are critical to actually reaching senolytic plasma levels.
Diminishing returns: Very high doses (>30 mg/kg human equivalent) do not appear to produce proportionally greater senolytic effects and increase risk of GI side effects.
As an Amazon Associate, Stacking Years earns from qualifying purchases.
Does taking more than 20 mg/kg provide additional senolytic benefit?
Evidence does not support significant additional benefit above the 20 mg/kg human protocol. GI tolerability decreases at higher doses without proportional senolytic improvement.
Can I use continuous low-dose fisetin as a substitute for burst dosing?
Low-dose continuous fisetin (100–200 mg/day) provides non-senolytic benefits but does not achieve senolytic plasma levels. Burst dosing is essential for senolytic action. Both approaches can be combined.
How do I know if my fisetin is reaching senolytic plasma levels?
At present, there is no convenient home test for plasma fisetin levels. Surrogate biomarkers (high-sensitivity CRP, IL-6, p16 mRNA from blood tests) may indicate senolytic activity over time.
Get the free Longevity Supplement Starter Guide
Sign up for the guide and occasional Stacking Years updates. The guide is available on the confirmation screen.
Scientific References
Yousefzadeh MJ et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018. PMID: 30279143
Zhu Y et al. New agents that target senescent cells: the flavone, fisetin, and BCL-XL inhibitors. Aging. 2017. PMID: 28900009